Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOVANYSE:OGNNASDAQ:PTCTNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOVAIovance Biotherapeutics$3.06-0.5%$4.00$2.70▼$14.23$1.00B1.057.45 million shs9.65 million shsOGNOrganon & Co.$11.11+2.7%$14.32$10.75▼$23.10$2.87B0.732.66 million shs2.93 million shsPTCTPTC Therapeutics$47.39+2.1%$50.22$24.00▼$58.38$3.74B0.58821,653 shs1.04 million shsRYTMRhythm Pharmaceuticals$61.74+0.7%$54.70$35.17▼$68.58$3.90B2.32542,478 shs628,803 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOVAIovance Biotherapeutics-0.49%-0.16%-14.43%-48.31%-74.11%OGNOrganon & Co.+2.57%-2.80%-29.23%-29.54%-37.84%PTCTPTC Therapeutics+2.11%+17.62%-14.57%+8.10%+88.35%RYTMRhythm Pharmaceuticals+0.65%+6.76%+18.07%+13.20%+60.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIOVAIovance Biotherapeutics4.2355 of 5 stars4.41.00.04.22.52.50.6OGNOrganon & Co.4.793 of 5 stars3.23.03.33.72.51.73.1PTCTPTC Therapeutics3.7608 of 5 stars4.31.00.04.42.60.80.0RYTMRhythm Pharmaceuticals3.9146 of 5 stars3.52.00.04.33.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOVAIovance Biotherapeutics 2.89Moderate Buy$18.22496.47% UpsideOGNOrganon & Co. 2.43Hold$20.6085.45% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$63.7734.56% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$74.9221.35% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, RYTM, PTCT, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $16.004/14/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $5.004/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.004/8/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/8/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $92.004/8/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $80.004/7/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $91.004/7/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$63.00 ➝ $63.003/31/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$78.00 ➝ $75.003/24/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/18/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$64.00 ➝ $66.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOVAIovance Biotherapeutics$164.07M6.11N/AN/A$2.28 per share1.34OGNOrganon & Co.$6.40B0.45$3.56 per share3.12($0.27) per share-41.14PTCTPTC Therapeutics$806.78M4.63$2.28 per share20.80($10.85) per share-4.37RYTMRhythm Pharmaceuticals$130.13M30.00N/AN/A$2.87 per share21.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOVAIovance Biotherapeutics-$444.04M-$1.30N/AN/AN/A-451.25%-58.43%-45.48%5/8/2025 (Estimated)OGNOrganon & Co.$864M$3.333.342.970.9013.49%431.62%8.03%5/1/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/6/2025 (Estimated)Latest IOVA, RYTM, PTCT, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25N/AN/AN/A$83.40 millionN/A5/6/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.67N/AN/AN/A$40.43 millionN/A5/1/2025Q1 2025OGNOrganon & Co.$0.92N/AN/AN/A$1.53 billionN/A4/24/2025Q1 2025PTCTPTC Therapeutics$0.85N/AN/AN/A$437.16 millionN/A2/27/2025Q4 2024IOVAIovance Biotherapeutics-$0.26-$0.26N/A-$0.26$72.17 million$73.69 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$1.1210.08%+25.99%33.63%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ALatest IOVA, RYTM, PTCT, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOVAIovance BiotherapeuticsN/A4.223.90OGNOrganon & Co.17.731.701.21PTCTPTC TherapeuticsN/A2.102.04RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOVAIovance Biotherapeutics77.03%OGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipIOVAIovance Biotherapeutics12.10%OGNOrganon & Co.1.40%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOVAIovance Biotherapeutics500327.88 million267.90 millionOptionableOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableRYTMRhythm Pharmaceuticals14063.22 million58.02 millionOptionableIOVA, RYTM, PTCT, and OGN HeadlinesRecent News About These CompaniesNeedham & Company LLC Predicts RYTM FY2027 EarningsApril 18 at 8:42 AM | marketbeat.comEAM Global Investors LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 18 at 6:52 AM | marketbeat.comEAM Investors LLC Purchases Shares of 63,078 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 18 at 6:42 AM | marketbeat.com144,342 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Walleye Capital LLCApril 18 at 5:18 AM | marketbeat.comRYTM Q2 EPS Estimate Lifted by Needham & Company LLCApril 18 at 1:49 AM | americanbankingnews.comTrexquant Investment LP Buys Shares of 7,798 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 15 at 4:20 AM | marketbeat.comJPMorgan Chase & Co. Raises Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 14, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 8% - Here's What HappenedApril 11, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells 17,750 Shares of StockApril 11, 2025 | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $92.00April 11, 2025 | americanbankingnews.comRhythm Pharmaceuticals' (RYTM) "Buy" Rating Reiterated at Needham & Company LLCApril 11, 2025 | americanbankingnews.comRhythm Pharmaceuticals price target raised to $68 from $63 at BofAApril 11, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 11.9% After Analyst UpgradeApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns "Buy" Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC WainwrightApril 10, 2025 | marketbeat.comAmerican Century Companies Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading 11.9% Higher After Analyst UpgradeApril 10, 2025 | americanbankingnews.comWhy Rhythm Pharmaceuticals, Inc.’s (RYTM) Stock Is Down 10.71%April 10, 2025 | aaii.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Analyst UpgradeApril 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00 at Wells Fargo & CompanyApril 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, RYTM, PTCT, and OGN Company DescriptionsIovance Biotherapeutics NASDAQ:IOVA$3.06 -0.02 (-0.49%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$3.09 +0.03 (+1.15%) As of 04/17/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Organon & Co. NYSE:OGN$11.11 +0.29 (+2.66%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$11.06 -0.05 (-0.43%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$47.39 +0.98 (+2.11%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$47.42 +0.02 (+0.05%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$61.74 +0.40 (+0.65%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$61.94 +0.20 (+0.32%) As of 04/17/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
